Skip to content

Effects of Alpha-acid Lipoic in PCOS Women

Effects of 6 Months of Alpha-Lipoic Acid Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02666170
Enrollment
40
Registered
2016-01-28
Start date
2016-01-31
Completion date
Unknown
Last updated
2016-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

The aim of our study is to investigate the effects of six months treatment with alpha-lipoic acid on clinical, endocrine and metabolic features in women affected by PCOS. Menstrual pattern, anthropometric parameters, hirsutism score, ultrasound ovarian featureas, an oral glucose tolerance test and hormonal assays are evaluated before and after therapy.

Interventions

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* women with PCOS in accordance with Rotterdam criteria

Exclusion criteria

* pregnancy * past history of cardiovascular diseases * diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 gr oral glucose tolerance test) * hypertension * significant liver or renal impairment * other hormonal dysfunction (hypothalamic, pituitary, thiroidal or adrenal) * neoplasms.

Design outcomes

Primary

MeasureTime frame
Number of cycles in six months of therapy6 months

Secondary

MeasureTime frameDescription
Insulin levels6 months
androstenedione levels6 months
testosterone levels6 months
free androgen index6 months
Hirsutism score6 monthsFerriman-Gallwey score
LDL-cholesterol6 months
tryglycerides levels6 months
DHEAS levels6 months
AMH levels6 months
total cholesterol6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026